Nina Capital

Venture Capital Active Spain Est. 2019
Visit website ↗ LinkedIn
Last updated 2026-06-18
Portfolio
3
in our dataset
Rounds participated
5
Rounds led
0
Rounds' value
$23.8M
total disclosed, rounds participated
Stages
Pre-Seed, Seed, A Round

About

In the firm's investment criteria and process, they are informed by a Stanford-born methodology of health technology innovation known as Biodesign. Since 2001, Biodesign has proven to de-risk the process of new venture creation by applying a need-driven and value-based approach to reinventing healthcare with the help of technology.

The focal point lies in supporting founders who possess a deep comprehension of the intricate network of healthcare system stakeholders, coupled with significant engineering innovation, advanced data science, and information technology-enabled solutions. Operating primarily from Europe, the firm aim is to identify and assist founders driven by genuine needs, committed to serving these stakeholders on a global scale with effectiveness and efficiency.

The firm invests broadly across Europe, including the United Kingdom, in the United States, Canada, Israel, and Australia, with a collaborative approach in how they work and interact with other players in their industry. Their goal is to help thoughtful and committed teams bridge the chasm from founding to series A capital and access global markets.

Portfolio · 3

Magentiq Eye
Improving Colonoscopy through AI
2 rounds $2.0M committed Latest: 2025-07
QuantHealth
AI-Based Clinical Trial Simulation
2 rounds $17.6M committed Latest: 2023-08
Chiefy
Clinical Communication and Collaboration System
1 round $4.2M committed Latest: 2023-04

Investment activity

Portfolio by sector

Health Tech & Life Sciences3

Funds · 2

  • 2 — $43M Feb 2022
  • 1 — $19.5M Jun 2021

Q&A

What is Nina Capital's primary investment focus?
Nina Capital primarily invests in Health Tech & Life Sciences companies, with all three of its listed portfolio companies operating in this sector.
What is Nina Capital's geographic investment scope?
Nina Capital invests broadly across Europe, including the United Kingdom, in the United States, Canada, Israel, and Australia.
Which funding stages does Nina Capital typically target?
Nina Capital focuses on Pre-Seed, Seed, and A Round investment stages.
When did Nina Capital close its second fund?
Nina Capital closed its second fund, Fund 2, in February 2022, raising $43M.
What was the size of Nina Capital's first fund?
Nina Capital's first fund, Fund 1, closed in June 2021 with $19.5M.
Can you name a notable portfolio company of Nina Capital?
Nina Capital's portfolio includes QuantHealth, an AI-Based Clinical Trial Simulation company that raised a $21.01M Series A round.
Who is a key founder at Nina Capital?
Marta G. Zanchi is a Founder & Managing Partner at Nina Capital.
What is Nina Capital's investment methodology?
Nina Capital's investment criteria and process are informed by the Stanford-born Biodesign methodology of health technology innovation, which applies a need-driven and value-based approach.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)